Discover comprehensive details about Lutetium Lu 177 Dotatate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

The appraisal committee considered evidence from a number of sources. See the committee papers for full details of the evidence. The committee understood that neuroendocrine tumours (NETs) can affect ...

Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing ...

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...

Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

− Results show delivery of high radiation doses to tumours compared with normal organs. − Observed normal organ absorbed dosimetry results may allow administration of a high cumulative radioactivity.

Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production ...

At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG's radiopharmaceutical lutetium-177-PSMA-617 ...